Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 4, 2010, Pages 496-500

  Hao, Pan Pan ^a   Chen, Yu Guo ^a   Wang, Jia Li ^a   Ji, Wen Qing ^a   Xue, Li ^a   Liu, Xiang Hong ^b   Wang, Xing Li ^c   Zhang, Yun ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b SHANDONG UNIVERSITY   (China)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Coronary artery disease; High dose statin; Major adverse cardiac events; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; TICLOPIDINE; TROPONIN I;

ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HEART PROTECTION; HUMAN; MEDLINE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE TREATMENT; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; DISEASE PROGRESSION; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; PREMEDICATION; TROPONIN I;

EID: 77949904384     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05339.x     Document Type: Article

References (23)

1. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins: clinical evidence. Curr. Pharm. Des. 2009 15 : 479 489.
2. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis J. Am. Coll. Cardiol. 2005 46 : 1855 1862.
3. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur. Heart J. 2002 23 : 869 876.
4. Ioannidis JP, Karvouni E, Katritis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention. J. Am. Coll. Cardiol. 2003 42 : 1406 1411.
5. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc. Interv. 2004 62 : 193 197.
6. Briguori C, Colombo A, Airoldi F et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur. Heart J. 2004 25 : 1822 1828.
7. Veselka J, Procházková S, Duchonová R, Homolová I, Tesar D, Bybee KA. Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Heart Vessels. 2006 21 : 146 151.
8. Lev EI, Kornowski R, Vaknin-Assa H et al. Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am. J. Cardiol. 2009 103 : 165 169.
9. Zhang M, Que B, Nie SP, Kang J, Ma CS. The effect of pre-hospital statins therapy on incidence of in-hospital death and total MACCE in patients with PCI. J. Clin. Pharm. Ther. 2008 33 : 613 617.
10. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 1996 17 : 1 12.
11. Pasceri V, Patti G, Nusca A et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004 110 : 674 678.
12. Patti G, Pasceri V, Colonna G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J. Am. Coll. Cardiol. 2007 49 : 1272 1278.
13. Yun KH, Jeong MH, Oh SK et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int. J. Cardiol. 2008 137 : 246 251. Epub 13 August 2008; doi :.
14. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J. Am. Coll. Cardiol. 2009 54 : 558 565.
15. Briguori C, Visconti G, Focaccio A et al. Novel approaches for preventing or limiting events (NAPLES) II trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J. Am. Coll. Cardiol. 2009 54 : 2157 2163.
16. Sposito AC, Chapman J. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler. Thromb. Vasc. Biol. 2002 22 : 1524 1534.
17. Lincoff AM, Tcheng JE, Califf RM et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade. Circulation 1999 99 : 1951 1958.
18. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005 111 : 2099 2106.
19. Bonz AW, Lengenfelder B, Strotmann J et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J. Am. Coll. Cardiol. 2002 40 : 662 668.
20. Li L, Liu RY, Zhao XY, Zhang JY, Jia M, Lu PQ. Effects of combination therapy with perindopril and losartan on left ventricular remodelling in patients with myocardial infarction. Clin. Exp. Pharmacol. Physiol. 2009 36 : 704 710.
21. Xu JW, Ikeda K, Ikami T, Yamori Y. Oleic acid inhibits C-reactive protein-induced expression of inducible nitric oxide synthase in rat aortic smooth muscle cells. Clin. Exp. Pharmacol. Physiol. 2007 34 (Suppl. S58 60.
22. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J. Am. Coll. Cardiol. 2003 42 : 1412 1414.
23. Otokozawa S, Ai M, Van Himbergen T et al. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis. 2009 205 : 197 201.